Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kadian Revenue Jump Offsets Alpharma's Loss Of Gabapentin Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Increased sales and marketing efforts have driven the extended-release morphine's weekly prescription rates above 10,000.

You may also be interested in...

FDA Requests Expanded Alcohol Warnings For Extended-Release Morphine Kadian

Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million

Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts